Lacrimal Stability Evaluation (Three-Dimensional Image Analysis of Anterior Segment) with Rebamipide Ophthalmic Solution

Lacrimal Stability Evaluation (Three-Dimensional Image Analysis of Anterior Segment) with Rebamipide Ophthalmic Solution - Lacrimal Stability Evaluation with Rebamipide Ophthalmic Solution

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017305

Enrollment

Registered

2015-05-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

Rebamipide ophthalmic solution 4 times / day, 4weeks Control saline eyedrops 4 times / day, 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who be classified the definition and diagnosis of Dry Eye 2006 and 20 years old or older 2) Patients who be obtained informed consent

Exclusion criteria

Exclusion criteria: 1) Epiphora with suspicion (caused by Allergic conjumctivitis) 2) Meibomian grand dysfunction 3) Atresia puncti lacrimalis (e.g., punctal plug, surgical punctal occlusion) 4) Complication with the upheaval of the keratoconjunctive (e.g., conjunctivochalasis, pterygium) 5) Anatomical and functionl palpebral abnormality (e.g., lid closure imperfection) 6) Instillation of the glaucoma therapeutic drug 7) Patients who cannot be obtained informed consent

Design outcomes

Primary

Measure	Time frame
To evaluate tear stability treated with rebamipide ophthalmic solution	—

Countries

Japan

Contacts

Public ContactAtsushi Shiraishi

Ehime University Ophthalmology

shiraia@m.ehime-u.ac.jp089-960-5361

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026